A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. (Q39586897)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 April 2014

Language	Label	Description	Also known as
English	A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study.	scientific article published on 28 April 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

multicenter clinical trial

0 references

macular degeneration

1 reference

based on heuristic

inferred from title

Sergio Pagliarini

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Blandina Lipkova

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Margarita Gekkieva

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Stephen Beatty

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Eduardo Perez-Salvador Garcia

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Stefaan Reynders

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Abdelkader Si Bouazza

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Stefan Pilz

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

28 April 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Journal of Ophthalmology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

857148

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

14 September 2017

Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

14 September 2017

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

14 September 2017

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

14 September 2017

One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

14 September 2017

Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

14 September 2017

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

14 September 2017

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

14 September 2017

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

14 September 2017

Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

21 August 2018

The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

21 August 2018

Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

21 August 2018

Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

21 August 2018

Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4020221

21 August 2018

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/24868458

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24868458

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24868458

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24868458

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24868458

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EXTEND III: efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD

1 reference

https://pubmed.ncbi.nlm.nih.gov/24868458

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24868458

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24868458

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results

1 reference

https://pubmed.ncbi.nlm.nih.gov/24868458

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2014/857148

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24868458%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39586897&oldid=1798345820"